



# NEMEX

## RESOURCES LIMITED

ACN 146 243 843



**15 September 2014**

### **Fast Facts**

#### **Capital Structure**

Shares on issue	168.0M
Options	97.5M
Performance Rights	9.0M
ASX Code	NXR

#### **Directors & Senior Management**

**Patrick Flint**

Chairman

**Peter Turner**

Non-Exec Director

**Paul Jurman**

Non-Exec Director &  
Company Secretary

#### **Project Highlights**

##### **WBT Investment**

- Biometric technology
- *Potential global market*
- *Strong management*

##### **Guinea (Iron)**

- *High-grade iron discovery*
- *Large resource potential*
- *Targeting DSO production*

##### **Côte d'Ivoire (Gold)**

- *Geophysical anomalies*
- *Exciting opportunity*
- *Under-explored country*

#### **Contacts**

**Mr Patrick Flint**

T: +61 8 9388 2277

[www.nemexres.com.au](http://www.nemexres.com.au)

## **Completion of Capital Raising**

Further to its announcement dated 8 September 2014, Nemex Resources Ltd (ASX: NXR) confirms that it has issued 10,562,522 shares at an issue price of 2 cents per share, together with 10,562,522 attaching options (exercisable at 5 cents on or before 31 December 2015) to raise \$211,250. The capital raising was managed by Cicero Advisory Services Pty Ltd.

The monies will provide funding for NXR's ongoing working capital requirements. NXR has no plans to raise further funds until WBT completes the next phase of its development program, which is expected to take 6 months to complete. The next phase will focus on improving the design and performance of the prototype unit, and will also involve commencement of commercialisation discussions with participants in the financial services and military / defence sectors.

The Company provides notice pursuant to ASX Listing Rule 3.10.5A that:

(a) Dilution to existing shareholders as a result of the issue


A total of 10,562,522 shares were issued pursuant to Listing Rule 7.1A, representing 6.29% of the post-placement capital. The balance of the capital raising, comprising 10,562,522 attaching options was completed under the Company's 15% capacity.

The percentage of the post-placement capital held in aggregate by pre-placement security holders who did not participate in the placement is 90.44%; the percentage of the post-placement capital held in aggregate by pre-placement security holders who did participate in the placement is 5.20% and the percentage of the post-placement capital held in aggregate by participants in the placement who were not previously security holders is 4.36%.

(b) The Company issued shares to sophisticated investors as it was considered to be the most efficient and expedient method for raising the funds required to achieve the stated objectives. NXR completed a pro rata issue to shareholders in August 2013.

(c) No underwriting arrangements were in place for the placement.

(d) Commission for the placement was 6% (plus GST) of the total funds raised.



An Appendix 3B is attached with respect to the new securities issued and the Company gives notice that:

- it issued the securities without disclosure to investors under Part 6D.2 of the Corporations Act 2001 (“Act”);
- this notice is being given under section 708A(5)(e) of the Act;
- as at today’s date, the Company has complied with:
  - (i) the provisions of Chapter 2M of the Act as they apply to the Company; and
  - (ii) section 674 of the Act; and
- as at today’s date there is no other information that is excluded information which is required to be set out in this notice pursuant to section 708A(6)(e) of the Act.

Yours faithfully



Paul Jurman

Company Secretary

Detailed information about Nemex is available at [www.nemexres.com.au](http://www.nemexres.com.au)

**For further information about Nemex and its investment in WBT contact:**

Patrick Flint

Chairman

P: 08 9388 2277

E: [pflint@nemexres.com.au](mailto:pflint@nemexres.com.au)

**About Nemex Resources**

Nemex Resources Ltd (ASX: NXR) boasts a diversified asset portfolio comprising interests in both the minerals and technology sectors.

Nemex has a 30% interest in Australian-based biometric technology developer Wavefront Biometric Technologies (WBT), and has the right to increase this to a 51% interest.

WBT is in the process of developing and commercialising a unique identity authentication technology. The technology authenticates a person’s identity based on the pattern of light reflected back from the tear film on the corneal surface of the eye. The technology has potential applications across numerous sectors around the world, including banking, healthcare, military, aviation and border control.

Nemex also holds interests in a number of highly prospective resources projects, including the Télimélé DSO Iron project in Guinea, early stage gold exploration prospects in Côte d’Ivoire and the Woodley Iron project in Western Australia.

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## Appendix 3B

### New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

**Nemex Resources Limited**

ABN

44 146 243 843

We (the entity) give ASX the following information.

### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

- |   |   |  |
|---|---|--|
| 1 | +Class of +securities issued or to be issued  | Ordinary shares and unlisted options   |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued   | 10,562,522 Ordinary shares and 10,562,522 unlisted options   |
| 3 | Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | Fully paid ordinary shares ranking equally with existing shares.<br><br>Each unlisted option is to subscribe for one ordinary share at an issue price of 5 cents, with an expiry date of 31 December 2015. |

+ See chapter 19 for defined terms.

## Appendix 3B

### New issue announcement

---

4	<p>Do the <sup>+</sup>securities rank equally in all respects from the <sup>+</sup>issue date with an existing <sup>+</sup>class of quoted <sup>+</sup>securities?</p> <p>If the additional <sup>+</sup>securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	<p>The ordinary shares rank equally with existing quoted shares (NXR)</p> <p>The unlisted options do not rank equally with an existing class of quoted securities.</p>
5	Issue price or consideration	Ordinary shares at 2 cents each with free attaching unlisted options.
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	To assist with general working capital.
6a	<p>Is the entity an <sup>+</sup>eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h <i>in relation to the <sup>+</sup>securities the subject of this Appendix 3B</i>, and comply with section 6i</p>	Yes.
6b	The date the security holder resolution under rule 7.1A was passed	27 November 2013.
6c	Number of <sup>+</sup> securities issued without security holder approval under rule 7.1	10,562,522 unlisted options.
6d	Number of <sup>+</sup> securities issued with security holder approval under rule 7.1A	10,562,522 Ordinary shares.
6e	Number of <sup>+</sup> securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

6f	Number of +securities issued under an exception in rule 7.2	N/A						
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	Yes. Issue price: \$0.02 Date on which the price at which the securities were issued was agreed: 5 September 2014. 15 day VWAP: \$0.021 (source IRESS)						
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A						
6i	Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	13,053,099 - Listing rule 7.1. 5,181,225 – Listing rule 7.1A.						
7	+Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	15 September 2014.						
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	<table><tr><th>Number</th><th>+Class</th></tr><tr><td>168,000,000</td><td>Ordinary Shares (NXR).</td></tr><tr><td>59,906,241</td><td>Options exercisable at 5 cents on or before 31 December 2014. (NXROA)</td></tr></table>	Number	+Class	168,000,000	Ordinary Shares (NXR).	59,906,241	Options exercisable at 5 cents on or before 31 December 2014. (NXROA)
Number	+Class							
168,000,000	Ordinary Shares (NXR).							
59,906,241	Options exercisable at 5 cents on or before 31 December 2014. (NXROA)							

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

---

	Number	+Class
9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	2,000,000	Unlisted Options exercisable at 5 cents on or before 1 November 2014
	35,562,522	Unlisted Options exercisable at 5 cents on or before 31 December 2015
	9,000,000	Performance Rights converting to fully paid ordinary shares on a 1 for 1 basis on satisfaction of specified conditions
10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	No plans to pay dividends at this stage.	

**Part 2 - Pro rata issue Not Applicable**

11 Is security holder approval required?	
12 Is the issue renounceable or non-renounceable?	
13 Ratio in which the +securities will be offered	
14 +Class of +securities to which the offer relates	
15 +Record date to determine entitlements	
16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17 Policy for deciding entitlements in relation to fractions	

---

+ See chapter 19 for defined terms.

18	Names of countries in which the entity has security holders who will not be sent new offer documents  <small>Note: Security holders must be told how their entitlements are to be dealt with.</small>  <small>Cross reference: rule 7.7.</small>	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	

---

+ See chapter 19 for defined terms.

## Appendix 3B

### New issue announcement

---

32 How do security holders dispose of their entitlements (except by sale through a broker)?

33 <sup>+</sup>Issue date

## Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

34 Type of <sup>+</sup>securities  
(tick one)

(a) ☒ <sup>+</sup>Securities described in Part 1 – only with respect to ordinary shares.

(b) ☐ All other <sup>+</sup>securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents*

35 ☐ If the <sup>+</sup>securities are <sup>+</sup>equity securities, the names of the 20 largest holders of the additional <sup>+</sup>securities, and the number and percentage of additional <sup>+</sup>securities held by those holders

36 ☐ If the <sup>+</sup>securities are <sup>+</sup>equity securities, a distribution schedule of the additional <sup>+</sup>securities setting out the number of holders in the categories  
1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over

37 ☐ A copy of any trust deed for the additional <sup>+</sup>securities

---

<sup>+</sup> See chapter 19 for defined terms.

**Entities that have ticked box 34(b)**

38	Number of +securities for which +quotation is sought					
39	+Class of +securities for which quotation is sought					
40	<p>Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>					
41	<p>Reason for request for quotation now</p> <p><small>Example: In the case of restricted securities, end of restriction period</small></p> <p>(if issued upon conversion of another +security, clearly identify that other +security)</p>					
42	Number and +class of all +securities quoted on ASX ( <i>including</i> the +securities in clause 38)	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 50%; text-align: center;">Number</th> <th style="width: 50%; text-align: center;">+Class</th> </tr> </thead> <tbody> <tr style="height: 80px;"> <td></td> <td></td> </tr> </tbody> </table>	Number	+Class		
Number	+Class					

---

+ See chapter 19 for defined terms.

**Quotation agreement**

- 1      +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2      We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
  - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
  - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3      We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4      We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here: ..... Date: 15 September 2014.  
(Director/Company secretary)  
Print name: P Jurman  
== == == == ==

---

+ See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

Rule 7.1 – Issues exceeding 15% of capital	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>Insert</b> number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	42,625,001
<b>Add</b> the following: <ul style="list-style-type: none"> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> </ul> <b>Note:</b> <ul style="list-style-type: none"> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	1,000,000 ordinary shares issued on conversion of performance rights  6,320,319 fully paid ordinary shares issued on 23 August 2013 to holders of securities who participated in the Non-Renounceable Entitlement Issue.  15,492,158 fully paid ordinary shares issued on 28 August 2013 to investors who participated in the shortfall arising out of the Non-Renounceable Entitlement Issue.  10,000,000 fully paid ordinary shares issued on 2 April 2014 as part of a private placement to sophisticated investors.  80,000,000 fully paid ordinary shares issued on 15 May 2014 as part of a private placement to sophisticated investors.  1,500,000 fully paid ordinary shares issued on 15 May 2014 as an Introduction fee in relation to the WBT Transaction.  500,000 fully paid ordinary shares issued on 15 May 2014 as part of the remuneration package for Dr Turner.
<b>Subtract</b> the number of fully paid +ordinary securities cancelled during that 12 month period	Nil

+ See chapter 19 for defined terms.

**Appendix 3B**  
**New issue announcement**

<b>“A”</b>	157,437,478
<b>Step 2: Calculate 15% of “A”</b>	
<b>“B”</b>	0.15 <i>[Note: this value cannot be changed]</i>
<b>Multiply “A” by 0.15</b>	23,615,621
<b>Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used</b>	
<p><b>Insert</b> number of <sup>+</sup>equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> <li>• Under an exception in rule 7.2</li> <li>• Under rule 7.1A</li> <li>• With security holder approval under rule 7.1 or rule 7.4</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	10,562,522 unlisted options issued free on 15 September 2014 as part of a private placement to sophisticated investors.
<b>“C”</b>	<b>10,562,522</b>
<b>Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1</b>	
<b>“A” x 0.15</b>  <i>Note: number must be same as shown in Step 2</i>	23,615,621
<b>Subtract “C”</b>  <i>Note: number must be same as shown in Step 3</i>	10,562,522
<b>Total [“A” x 0.15] – “C”</b>	13,053,099.  <i>[Note: this is the remaining placement capacity under rule 7.1]</i>

+ See chapter 19 for defined terms.

## Part 2

<b>Rule 7.1A – Additional placement capacity for eligible entities</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>“A”</b> <i>Note: number must be same as shown in Step 1 of Part 1</i>	157,437,478
<b>Step 2: Calculate 10% of “A”</b>	
<b>“D”</b>	0.10 <i>Note: this value cannot be changed</i>
<b>Multiply “A” by 0.10</b>	15,743,747
<b>Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used</b>	
<b>Insert</b> number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A  <i>Notes:</i> <ul style="list-style-type: none"> <li>• This applies to equity securities – not just ordinary securities</li> <li>• Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>• Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>• It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	10,562,522 fully paid ordinary shares issued on 15 September 2014 as part of a private placement to sophisticated investors.
<b>“E”</b>	-
<b>Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A</b>	
<b>“A” x 0.10</b> <i>Note: number must be same as shown in Step 2</i>	15,743,747
<b>Subtract “E”</b> <i>Note: number must be same as shown in Step 3</i>	10,562,522
<b>Total [“A” x 0.10] – “E”</b>	5,181,225 <i>Note: this is the remaining placement capacity under rule 7.1A</i>

+ See chapter 19 for defined terms.